Tislelizumab plus nintedanib as consolidation therapy for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two drugs (tislelizumab and nintedanib) given after initial chemotherapy and radiation to help prevent the cancer from coming back. It is for people with limited-stage small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have limited-stage small cell lung cancer (meaning it's only in one side of the chest and nearby areas).
- You have at least one tumor that can be measured on a scan.
- You are in generally good health for your age (ECOG score 0 or 1), which means you can do most daily activities.
- You have already completed your initial chemotherapy and radiation, but you haven't had other treatments like immunotherapy or targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a new combination of an immunotherapy drug, a targeted therapy, and standard chemotherapy plus radiation for people with limited-stage small cell lung cancer. It aims to see if this combination improves outcomes compared to standard treatment alone.
This trial tests whether adding two medications—tislelizumab (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted drug that blocks blood supply to tumors)—after standard chemoradiation can help keep limited-stage small cell lung cancer from coming back. It may offer a new option to improve outcomes for patients who have already responded to initial treatment.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Hear when a new Limited-stage Small Cell Lung Cancer (LS-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.